Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lipoproteins, LDL | 34 | 2019 | 343 | 5.370 |
Why?
|
| Antigen-Antibody Complex | 28 | 2019 | 175 | 3.540 |
Why?
|
| Autoantibodies | 13 | 2017 | 434 | 2.850 |
Why?
|
| Atherosclerosis | 6 | 2017 | 204 | 1.880 |
Why?
|
| Diabetes Mellitus, Type 1 | 17 | 2019 | 529 | 1.440 |
Why?
|
| Immunoglobulin G | 9 | 2016 | 481 | 1.030 |
Why?
|
| Macrophages | 10 | 2017 | 647 | 0.980 |
Why?
|
| Malondialdehyde | 6 | 2017 | 43 | 0.960 |
Why?
|
| Glycation End Products, Advanced | 10 | 2019 | 125 | 0.920 |
Why?
|
| Cardiovascular Diseases | 4 | 2019 | 938 | 0.790 |
Why?
|
| Diabetic Nephropathies | 7 | 2016 | 161 | 0.770 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2016 | 1085 | 0.700 |
Why?
|
| Lipoproteins | 4 | 2008 | 161 | 0.670 |
Why?
|
| Albuminuria | 7 | 2016 | 171 | 0.600 |
Why?
|
| Inflammation | 9 | 2017 | 1030 | 0.590 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2016 | 48 | 0.570 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2017 | 125 | 0.560 |
Why?
|
| Receptors, Immunologic | 1 | 2016 | 72 | 0.560 |
Why?
|
| Disease Progression | 11 | 2019 | 1037 | 0.540 |
Why?
|
| Diabetic Angiopathies | 5 | 2015 | 203 | 0.520 |
Why?
|
| E-Selectin | 6 | 2017 | 44 | 0.500 |
Why?
|
| Biomarkers | 12 | 2019 | 1593 | 0.490 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 4 | 2017 | 27 | 0.430 |
Why?
|
| Immunoglobulin M | 2 | 2013 | 172 | 0.410 |
Why?
|
| Apoptosis | 2 | 2017 | 1640 | 0.390 |
Why?
|
| Antibody Formation | 3 | 2008 | 93 | 0.390 |
Why?
|
| Interleukin-6 | 6 | 2017 | 330 | 0.370 |
Why?
|
| Arteriosclerosis | 5 | 2003 | 137 | 0.360 |
Why?
|
| Antibodies | 5 | 2010 | 241 | 0.360 |
Why?
|
| Allergy and Immunology | 1 | 2009 | 9 | 0.350 |
Why?
|
| Immunity, Humoral | 1 | 2009 | 42 | 0.340 |
Why?
|
| Diabetes Complications | 5 | 2017 | 249 | 0.330 |
Why?
|
| Humans | 48 | 2019 | 68525 | 0.320 |
Why?
|
| Lysine | 2 | 2005 | 96 | 0.310 |
Why?
|
| Receptors, IgG | 4 | 2017 | 94 | 0.310 |
Why?
|
| Endothelium, Vascular | 5 | 2015 | 371 | 0.310 |
Why?
|
| Cytokines | 5 | 2017 | 866 | 0.280 |
Why?
|
| Animals | 13 | 2019 | 20877 | 0.270 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 3 | 2017 | 27 | 0.270 |
Why?
|
| Antibodies, Heterophile | 1 | 2004 | 11 | 0.250 |
Why?
|
| Simvastatin | 1 | 2004 | 34 | 0.240 |
Why?
|
| Adjuvants, Immunologic | 1 | 2004 | 63 | 0.240 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 507 | 0.230 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 4 | 2017 | 58 | 0.220 |
Why?
|
| Phagocytosis | 2 | 2013 | 65 | 0.220 |
Why?
|
| Diabetic Retinopathy | 2 | 2014 | 109 | 0.220 |
Why?
|
| Receptors, LDL | 4 | 2016 | 72 | 0.210 |
Why?
|
| Autoimmunity | 1 | 2002 | 118 | 0.210 |
Why?
|
| Oxidation-Reduction | 4 | 2009 | 567 | 0.190 |
Why?
|
| Sphingolipids | 2 | 2019 | 337 | 0.160 |
Why?
|
| Male | 21 | 2019 | 37281 | 0.160 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2017 | 59 | 0.150 |
Why?
|
| Diabetes Mellitus | 1 | 2003 | 693 | 0.150 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2017 | 74 | 0.150 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2015 | 54 | 0.150 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 101 | 0.150 |
Why?
|
| Caspase 3 | 1 | 2017 | 233 | 0.140 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2017 | 160 | 0.140 |
Why?
|
| Adult | 16 | 2019 | 21375 | 0.140 |
Why?
|
| Aorta | 2 | 2016 | 316 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 626 | 0.140 |
Why?
|
| Cholesterol, LDL | 3 | 2012 | 161 | 0.130 |
Why?
|
| Cholesterol Esters | 2 | 1991 | 26 | 0.130 |
Why?
|
| Cholesterol | 5 | 2017 | 331 | 0.130 |
Why?
|
| Kidney Diseases | 1 | 2017 | 307 | 0.130 |
Why?
|
| Mice | 5 | 2016 | 8472 | 0.130 |
Why?
|
| Gene Expression | 1 | 2017 | 770 | 0.130 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 121 | 0.130 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2016 | 195 | 0.120 |
Why?
|
| Kidney | 1 | 2019 | 945 | 0.120 |
Why?
|
| Apolipoproteins B | 2 | 2004 | 29 | 0.120 |
Why?
|
| Rabbits | 2 | 2005 | 509 | 0.120 |
Why?
|
| Cell Line | 3 | 2013 | 1752 | 0.120 |
Why?
|
| Female | 19 | 2019 | 38015 | 0.120 |
Why?
|
| Capillaries | 1 | 2014 | 105 | 0.120 |
Why?
|
| C-Reactive Protein | 4 | 2017 | 180 | 0.120 |
Why?
|
| Immunoassay | 1 | 2013 | 64 | 0.110 |
Why?
|
| Pericytes | 1 | 2014 | 81 | 0.110 |
Why?
|
| Macrophage Activation | 2 | 2010 | 75 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 244 | 0.110 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 3256 | 0.110 |
Why?
|
| Immunoglobulin Isotypes | 2 | 2009 | 28 | 0.110 |
Why?
|
| Retina | 1 | 2014 | 252 | 0.100 |
Why?
|
| Mice, Knockout | 1 | 2016 | 1692 | 0.100 |
Why?
|
| Cohort Studies | 6 | 2016 | 2356 | 0.100 |
Why?
|
| Collagen Type IV | 1 | 2011 | 28 | 0.100 |
Why?
|
| Glomerular Mesangium | 1 | 2011 | 53 | 0.100 |
Why?
|
| Mesangial Cells | 1 | 2011 | 37 | 0.100 |
Why?
|
| Young Adult | 6 | 2019 | 5708 | 0.100 |
Why?
|
| Epitopes | 2 | 2016 | 146 | 0.090 |
Why?
|
| Ceramides | 1 | 2014 | 578 | 0.090 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2012 | 183 | 0.090 |
Why?
|
| Tunica Media | 2 | 2008 | 33 | 0.090 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2010 | 42 | 0.090 |
Why?
|
| Tunica Intima | 2 | 2008 | 59 | 0.090 |
Why?
|
| Middle Aged | 9 | 2017 | 21119 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2008 | 1548 | 0.090 |
Why?
|
| Osmolar Concentration | 2 | 2010 | 134 | 0.080 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2008 | 41 | 0.080 |
Why?
|
| Immunity, Cellular | 1 | 2008 | 80 | 0.080 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2008 | 77 | 0.080 |
Why?
|
| Risk Factors | 6 | 2019 | 5719 | 0.080 |
Why?
|
| Chemokines | 1 | 2008 | 119 | 0.080 |
Why?
|
| Adolescent | 6 | 2019 | 8903 | 0.080 |
Why?
|
| Monocytes | 1 | 2008 | 210 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2011 | 250 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 1465 | 0.070 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 807 | 0.070 |
Why?
|
| Protein Transport | 3 | 2014 | 280 | 0.070 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2017 | 45 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2010 | 718 | 0.070 |
Why?
|
| Time Factors | 4 | 2014 | 4655 | 0.070 |
Why?
|
| Blood Coagulation | 2 | 2017 | 123 | 0.070 |
Why?
|
| Carotid Artery, Internal | 1 | 2006 | 85 | 0.070 |
Why?
|
| Foam Cells | 3 | 2008 | 26 | 0.070 |
Why?
|
| Diphtheria-Tetanus Vaccine | 1 | 2005 | 5 | 0.070 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2005 | 4 | 0.070 |
Why?
|
| Hepatitis B Vaccines | 1 | 2005 | 11 | 0.070 |
Why?
|
| Complement System Proteins | 1 | 2006 | 135 | 0.060 |
Why?
|
| Cross Reactions | 1 | 2004 | 57 | 0.060 |
Why?
|
| Antibody Specificity | 1 | 2004 | 98 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2012 | 791 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2008 | 1341 | 0.060 |
Why?
|
| Cell Survival | 3 | 2014 | 901 | 0.060 |
Why?
|
| U937 Cells | 3 | 2010 | 61 | 0.060 |
Why?
|
| Calibration | 1 | 2003 | 73 | 0.060 |
Why?
|
| Copper | 1 | 2005 | 149 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 1 | 2003 | 61 | 0.060 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2002 | 13 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 196 | 0.050 |
Why?
|
| Triglycerides | 2 | 2017 | 184 | 0.050 |
Why?
|
| Th1 Cells | 1 | 2003 | 101 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 1293 | 0.050 |
Why?
|
| Risk | 1 | 2003 | 563 | 0.050 |
Why?
|
| Prognosis | 3 | 2012 | 2093 | 0.050 |
Why?
|
| Lysosomes | 2 | 2012 | 136 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2014 | 2004 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 1753 | 0.050 |
Why?
|
| Incidence | 2 | 2016 | 1582 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 2077 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2013 | 737 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2005 | 696 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2003 | 753 | 0.040 |
Why?
|
| Glycosylation | 1 | 2019 | 185 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2014 | 848 | 0.040 |
Why?
|
| Fibrinolysis | 1 | 2017 | 55 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2017 | 52 | 0.040 |
Why?
|
| Hemocyanins | 2 | 2008 | 14 | 0.040 |
Why?
|
| Interleukin-10 | 2 | 2010 | 144 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2017 | 87 | 0.040 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 161 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2011 | 489 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2012 | 682 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 710 | 0.030 |
Why?
|
| Cholesterol, HDL | 2 | 2006 | 112 | 0.030 |
Why?
|
| Prevalence | 2 | 2013 | 1609 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 1851 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2017 | 3702 | 0.030 |
Why?
|
| Retinal Vasculitis | 1 | 2014 | 8 | 0.030 |
Why?
|
| Role | 1 | 2014 | 25 | 0.030 |
Why?
|
| Receptors, Scavenger | 1 | 2014 | 13 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2014 | 42 | 0.030 |
Why?
|
| Aged | 2 | 2014 | 14842 | 0.030 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2014 | 99 | 0.030 |
Why?
|
| Reference Values | 2 | 2005 | 579 | 0.030 |
Why?
|
| Chloroquine | 1 | 1991 | 21 | 0.030 |
Why?
|
| Sterol O-Acyltransferase | 1 | 1991 | 7 | 0.030 |
Why?
|
| Exosomes | 1 | 2012 | 44 | 0.030 |
Why?
|
| Esterification | 1 | 1991 | 25 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 499 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2013 | 880 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 2264 | 0.020 |
Why?
|
| Endosomes | 1 | 2010 | 45 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 254 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 43 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 929 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2010 | 85 | 0.020 |
Why?
|
| RNA | 1 | 2011 | 171 | 0.020 |
Why?
|
| Particle Size | 1 | 2010 | 201 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2006 | 2673 | 0.020 |
Why?
|
| South Carolina | 1 | 2016 | 2750 | 0.020 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2010 | 200 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 2008 | 110 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 434 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 331 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2010 | 295 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2013 | 1447 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 320 | 0.020 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2006 | 11 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2006 | 86 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2006 | 75 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 498 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2010 | 1663 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 1849 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2005 | 114 | 0.020 |
Why?
|
| Immunization Schedule | 1 | 2005 | 25 | 0.020 |
Why?
|
| Probability | 1 | 2005 | 244 | 0.020 |
Why?
|
| Complement Activation | 1 | 2006 | 145 | 0.020 |
Why?
|
| Exanthema | 1 | 2005 | 30 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 272 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2008 | 446 | 0.020 |
Why?
|
| Age Distribution | 1 | 2005 | 319 | 0.020 |
Why?
|
| Headache | 1 | 2005 | 68 | 0.020 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2003 | 9 | 0.010 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2003 | 18 | 0.010 |
Why?
|
| Mutagenesis | 1 | 2003 | 60 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2003 | 191 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2003 | 161 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 1046 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 226 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2003 | 235 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2005 | 631 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2014 | 7264 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 1419 | 0.010 |
Why?
|
| Transfection | 1 | 2003 | 782 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 562 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 1425 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 614 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 954 | 0.010 |
Why?
|
| Protein Binding | 1 | 2003 | 1027 | 0.010 |
Why?
|
| United States | 1 | 2012 | 7335 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 700 | 0.010 |
Why?
|
| In Vitro Techniques | 2 | 1991 | 765 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2000 | 358 | 0.010 |
Why?
|
| Mutation | 1 | 2003 | 1213 | 0.010 |
Why?
|
| Child | 1 | 2005 | 6400 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2003 | 2688 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1991 | 31 | 0.010 |
Why?
|
| Receptors, Fc | 1 | 1991 | 19 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1991 | 165 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1991 | 137 | 0.010 |
Why?
|